Acute interactions between l-DOPA and the neurotoxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine in mice
Identifieur interne : 004566 ( Main/Merge ); précédent : 004565; suivant : 004567Acute interactions between l-DOPA and the neurotoxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine in mice
Auteurs : C. Cleren [France] ; C. Vilpoux [France] ; N. Dourmap [France] ; J.-J Bonnet [France] ; J. Costentin [France]Source :
- Brain Research [ 0006-8993 ] ; 1999.
English descriptors
- KwdEn :
Abstract
We have compared the effects of an i.p. pretreatment with l-DOPA (200 mg/kg) associated with benserazide (25 mg/kg) on neurotoxic effects of either 6-hydroxydopamine (6-OHDA) (50 μg, 10 μl per mouse) or 1-methyl-4-phenylpyridinium (MPP+) (17.5 μg, 10 μl per mouse). The striatal dopamine (DA) content, the vesicular monoamine transporter (VMAT2) density, as well as the hypothalamic norepinephrine (NE) content were measured 8 days after treatments. The l-DOPA–benserazide pretreatment worsened by 65% the 6-OHDA-induced depletion in striatal DA. On the contrary, it reduced by 42% the MPP+-induced depletion in striatal DA and by 54% the MPP+-induced decrease in VMAT2 density. It was noticed that the l-DOPA–benserazide pretreatment did not modify the marked decrease in hypothalamic NE content induced by 6-OHDA.
Url:
DOI: 10.1016/S0006-8993(99)01420-1
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000A22
- to stream Istex, to step Curation: 000A20
- to stream Istex, to step Checkpoint: 001374
Links to Exploration step
ISTEX:2261F2F057DD049066721F2292C82F897D06F833Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Acute interactions between l-DOPA and the neurotoxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine in mice</title>
<author><name sortKey="Cleren, C" sort="Cleren, C" uniqKey="Cleren C" first="C" last="Cleren">C. Cleren</name>
</author>
<author><name sortKey="Vilpoux, C" sort="Vilpoux, C" uniqKey="Vilpoux C" first="C" last="Vilpoux">C. Vilpoux</name>
</author>
<author><name sortKey="Dourmap, N" sort="Dourmap, N" uniqKey="Dourmap N" first="N" last="Dourmap">N. Dourmap</name>
</author>
<author><name sortKey="Bonnet, J J" sort="Bonnet, J J" uniqKey="Bonnet J" first="J.-J" last="Bonnet">J.-J Bonnet</name>
</author>
<author><name sortKey="Costentin, J" sort="Costentin, J" uniqKey="Costentin J" first="J" last="Costentin">J. Costentin</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:2261F2F057DD049066721F2292C82F897D06F833</idno>
<date when="1999" year="1999">1999</date>
<idno type="doi">10.1016/S0006-8993(99)01420-1</idno>
<idno type="url">https://api.istex.fr/document/2261F2F057DD049066721F2292C82F897D06F833/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000A22</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A22</idno>
<idno type="wicri:Area/Istex/Curation">000A20</idno>
<idno type="wicri:Area/Istex/Checkpoint">001374</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001374</idno>
<idno type="wicri:doubleKey">0006-8993:1999:Cleren C:acute:interactions:between</idno>
<idno type="wicri:Area/Main/Merge">004566</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Acute interactions between l-DOPA and the neurotoxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine in mice</title>
<author><name sortKey="Cleren, C" sort="Cleren, C" uniqKey="Cleren C" first="C" last="Cleren">C. Cleren</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Unité de Neuropsychopharmacologie Expérimentale, UPRES-A CNRS 6036, IFRMP N° 23, Site universitaire du Madrillet, Avenue de l'Université, 76800 Saint-Etienne du Rouvray</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Normandie</region>
<region type="old region" nuts="2">Haute-Normandie</region>
<settlement type="city">Saint-Etienne du Rouvray</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vilpoux, C" sort="Vilpoux, C" uniqKey="Vilpoux C" first="C" last="Vilpoux">C. Vilpoux</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Unité de Neuropsychopharmacologie Expérimentale, UPRES-A CNRS 6036, IFRMP N° 23, Site universitaire du Madrillet, Avenue de l'Université, 76800 Saint-Etienne du Rouvray</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Normandie</region>
<region type="old region" nuts="2">Haute-Normandie</region>
<settlement type="city">Saint-Etienne du Rouvray</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dourmap, N" sort="Dourmap, N" uniqKey="Dourmap N" first="N" last="Dourmap">N. Dourmap</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Unité de Neuropsychopharmacologie Expérimentale, UPRES-A CNRS 6036, IFRMP N° 23, Site universitaire du Madrillet, Avenue de l'Université, 76800 Saint-Etienne du Rouvray</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Normandie</region>
<region type="old region" nuts="2">Haute-Normandie</region>
<settlement type="city">Saint-Etienne du Rouvray</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bonnet, J J" sort="Bonnet, J J" uniqKey="Bonnet J" first="J.-J" last="Bonnet">J.-J Bonnet</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Unité de Neuropsychopharmacologie Expérimentale, UPRES-A CNRS 6036, IFRMP N° 23, Site universitaire du Madrillet, Avenue de l'Université, 76800 Saint-Etienne du Rouvray</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Normandie</region>
<region type="old region" nuts="2">Haute-Normandie</region>
<settlement type="city">Saint-Etienne du Rouvray</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Costentin, J" sort="Costentin, J" uniqKey="Costentin J" first="J" last="Costentin">J. Costentin</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Unité de Neuropsychopharmacologie Expérimentale, UPRES-A CNRS 6036, IFRMP N° 23, Site universitaire du Madrillet, Avenue de l'Université, 76800 Saint-Etienne du Rouvray</wicri:regionArea>
<placeName><region type="region" nuts="2">Région Normandie</region>
<region type="old region" nuts="2">Haute-Normandie</region>
<settlement type="city">Saint-Etienne du Rouvray</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Brain Research</title>
<title level="j" type="abbrev">BRES</title>
<idno type="ISSN">0006-8993</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1999">1999</date>
<biblScope unit="volume">830</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="314">314</biblScope>
<biblScope unit="page" to="319">319</biblScope>
</imprint>
<idno type="ISSN">0006-8993</idno>
</series>
<idno type="istex">2261F2F057DD049066721F2292C82F897D06F833</idno>
<idno type="DOI">10.1016/S0006-8993(99)01420-1</idno>
<idno type="PII">S0006-8993(99)01420-1</idno>
<idno type="ArticleID">15555</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0006-8993</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenylpyridinium</term>
<term>6-Hydroxydopamine</term>
<term>Hypothalamic noradrenergic neuron</term>
<term>Neurotoxicity</term>
<term>Nigro-striatal dopaminergic neuron</term>
<term>Vesicular monoamine transporter type 2</term>
<term>l-DOPA</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We have compared the effects of an i.p. pretreatment with l-DOPA (200 mg/kg) associated with benserazide (25 mg/kg) on neurotoxic effects of either 6-hydroxydopamine (6-OHDA) (50 μg, 10 μl per mouse) or 1-methyl-4-phenylpyridinium (MPP+) (17.5 μg, 10 μl per mouse). The striatal dopamine (DA) content, the vesicular monoamine transporter (VMAT2) density, as well as the hypothalamic norepinephrine (NE) content were measured 8 days after treatments. The l-DOPA–benserazide pretreatment worsened by 65% the 6-OHDA-induced depletion in striatal DA. On the contrary, it reduced by 42% the MPP+-induced depletion in striatal DA and by 54% the MPP+-induced decrease in VMAT2 density. It was noticed that the l-DOPA–benserazide pretreatment did not modify the marked decrease in hypothalamic NE content induced by 6-OHDA.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004566 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004566 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:2261F2F057DD049066721F2292C82F897D06F833 |texte= Acute interactions between l-DOPA and the neurotoxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine in mice }}
This area was generated with Dilib version V0.6.29. |